Here are six takeaways:
1. Mazor issued securities representing 3.4 percent of its issued and outstanding share capital on a fully diluted basis at a price per American Depositary Share $21.84.
2. The second tranche investment totals $20 million.
3. The announcement of Mazor X Surgical Assurance Platform on July 12 spurred Medtronic to complete this second tranche investment.
4. Medtronic has now purchased a total of 1.96 million ADS’, accounting for 7.27 percent of Mazor’s issued and outstanding share capital on a fully diluted basis. This totals $31.9 million.
5. As of June 20, Mazor’s cash, cash equivalents and investments reached $47.5 million.
6. After the second equity investment, Mazor’s cash, cash equivalents and investments will reach $65 million with a fully diluted share count of about 53.9 million.
More articles on devices:
Orthopaedic Implant Company launches nail system for femoral midshaft and distal fractures: 5 things to know
Amedica, Mazor Robotics, InVivo Therapeutics & more: 18 key notes
Global medical electronics market to hit $60B by 2023 — 6 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
